Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.
Crismita DmelloAaron SonabendVíctor A ArrietaDaniel Yang ZhangDeepak KanojiaLi ChenAndrew GouldJiangshan ZhangSeong Jae KangJan WinterCraig HorbinskiChristina AmideiBalázs GyőrffyAlex CorderoCatalina Lee ChangBrandyn CastroPatrick HsuAtique U AhmedMaciej S LesniakRoger StuppAdam M SonabendPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our hypothesis generating study showed SSR3 as a putative biomarker for susceptibility to PTX, warranting its prospective clinical validation.
Keyphrases